Redeye regards Genovis’ Q1’22 report as solid and is encouraged to see continuously strong growth in the Enzyme business. Adjusted for the SEK 10m relating to the license agreement with Selecta, sales were in line with our expectations (SEK 22.6m versus our estimated SEK 22.9m).